Q-omics provides the consensus-scored RCAN1 profile across patient tissues and cancer cell-line models. RCAN1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RCAN1 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, RCAN1 protein abundance shows 19,774 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, KICH, and GBM as cancer lineages where RCAN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RCAN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RCAN1 survival associations across molecular data types. RCAN1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RCAN1 RNA expression–survival associations across cancer types. High RCAN1 expression shows unfavorable associations in MESO, LGG, STAD and LAML, but favorable associations in SKCM and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RCAN1 RNA expression.
This table summarizes RCAN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RCAN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RCAN1 shows lower tumor expression in KICH, KIRP, THCA, COAD, LIHC and LUAD. The KICH box plot shows higher RCAN1 RNA expression in normal versus tumor tissue (log2 FC = −3.711, t-test p < 0.001).
This table shows molecular features associated with RCAN1 in patient tissues and cancer cell lines. In patient samples, RCAN1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RCAN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
